95406-69-2Relevant academic research and scientific papers
Isoxazol-5(4H)-ones. X-Ray Crystal Structures of a 4-Hydroxyisoxazol-5(4H)-one and a -5(4H),5'(4'H)-dione Formed by Oxygen Oxidation of 3-tert-Butyl-4-methylisoxazol-5(4H)-one
Brehm, Lotte,Johansen, Joergen S.,Krogsgaard-Larsen, Povl
, p. 2059 - 2064 (1992)
Treatment of ethyl (RS)-2,4,4-trimethyl-3-oxopentanoate 4 with hydroxylamine under basic conditions gave 5-tert-butyl-4-methylisoxazol-3-ol 5 and a tautomeric mixture of 3-tert-butyl-4-methylisoxazol-5(2H)-one 6 and (RS)-3-tert-butyl-4-methylisoxazol-5(4H)-one 7.During the attempts to crystallize the inseparable mixture of tautomers 6 and 7 two other compounds, (RS)-3-tert-butyl-4-hydroxy-4-methylisoxazol-5(4H)-one 8 and (RS,RS)-3,3'-di-tert-butyl-4,4'-dimethyl--5(4H),5'(4'H)-dione 9, were progressively formed.The structure of compounds 8 and 9 were established by X-ray analyses.Compounds 8 and 9 are proposed to be formed by oxidation of compound 7 with oxygen, but the mechanisms underlying these two oxidative processes are unknown.
Indole-2,3-dione-3-oxime derivatives for therapeutic use
-
, (2008/06/13)
The present invention relates to the use of indole-2,3-dione-3-oxime derivatives in a method of combating diseases and disorders associated with or mediated by the release of excitatory amino acids.
Indole-2,3-dione-3-oxime derivatives
-
, (2008/06/13)
PCT No. PCT/DK97/00418 Sec. 371 Date Jun. 1, 1998 Sec. 102(e) Date Jun. 1, 1998 PCT Filed Oct. 1, 1997 PCT Pub. No. WO98/14447 PCT Pub. Date Apr. 9, 1998The present invention relates to novel indole-2,3-dione-3-oxime derivatives capable of antagonising th
Ibotenic Acid Analogues. Synthesis, Molecular Flexibility, and in Vitro Activity of Agonists and Antagonists at Central Glutamic Acid Receptors
Lauridsen, Joern,Honore, Tage,Krogsgaard-Larsen, Povl
, p. 668 - 672 (2007/10/02)
The syntheses of (RS)-α-amino-3-hydroxy-5-tert-butyl-4-isoxazolepropionic acid (9, ATPA), (α-RS,β-RS)-α-amino-β-methyl-3-hydroxy-5-isoxazolepropionic acid (8), (RS)-α-amino-3-hydroxy-5-isoxazolebutyric acid (15a), and (RS)-α-amino-3-hydroxy-5-isoxazoleval
